Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
May 11, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
May 29, 2019 - Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
Jun 05, 2019 - Ironwood (IRWD)and its partner initiate dosing in a phase II study evaluating delayed-release version of Linzess, MD-7246, in patients with IBS-D.
Jun 06, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.